These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 25982692)

  • 21. NT-ProBNP and cardiac troponin I in virulent canine babesiosis.
    Lobetti R; Kirberger R; Keller N; Kettner F; Dvir E
    Vet Parasitol; 2012 Dec; 190(3-4):333-9. PubMed ID: 22884910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical utility of serum N-terminal pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity.
    Oyama MA; Fox PR; Rush JE; Rozanski EA; Lesser M
    J Am Vet Med Assoc; 2008 May; 232(10):1496-503. PubMed ID: 18479239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NT-proBNP and cardiac troponin I concentrations in dogs with tick paralysis caused by Ixodes holocyclus.
    Nicolson GP; McGrath A; Webster RA; Li J; Kaye S; Malik R; Beijerink NJ
    Aust Vet J; 2016 Aug; 94(8):274-9. PubMed ID: 27461350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lowered N-terminal pro-B-type natriuretic peptide levels in response to treatment predict survival in dogs with symptomatic mitral valve disease.
    Wolf J; Gerlach N; Weber K; Klima A; Wess G
    J Vet Cardiol; 2012 Sep; 14(3):399-408. PubMed ID: 22858663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between glomerular filtration rate and plasma N-terminal pro B-type natriuretic peptide concentrations in dogs with chronic kidney disease.
    Miyagawa Y; Tominaga Y; Toda N; Takemura N
    Vet J; 2013 Aug; 197(2):445-50. PubMed ID: 23570775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between Survival Time and Changes in NT-proBNP in Cats Treated for Congestive Heart Failure.
    Pierce KV; Rush JE; Freeman LM; Cunningham SM; Yang VK
    J Vet Intern Med; 2017 May; 31(3):678-684. PubMed ID: 28370373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How accurate are NT-proBNP, ANP, and cTnI levels in diagnosing dogs with myxomatous mitral valve disease?
    Chanmongkolpanit K; Riengvirodkij N; Channgam P; Kaenchan P; Buayam W; Janhirun Y; Phonarknguen R; Tansakul M; Sakcamduang W
    Open Vet J; 2024 Jun; 14(6):1426-1441. PubMed ID: 39055758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of N-terminal pro-brain natriuretic peptide for assessing hemodynamic significance of patent ductus arteriosus in dogs undergoing ductal repair.
    Hariu CD; Saunders AB; Gordon SG; Norby B; Miller MW
    J Vet Cardiol; 2013 Sep; 15(3):197-204. PubMed ID: 23933478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [NT-proBNP as a diagnostic marker in dogs with dyspnea and in asymptomatic dogs with heart murmur].
    Haßdenteufel E; Kresken JG; Henrich E; Hildebrandt N; Schneider C; Stosic A; Schneider M
    Tierarztl Prax Ausg K Kleintiere Heimtiere; 2012; 40(3):171-9. PubMed ID: 22688794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparison study on diagnostic and prognostic value of N-terminal pro-brain natriuretic peptide and atrium natriuretic peptide in chronic congestive heart failure].
    Li YJ; Wang L; Chen KY; Chen YL; Cai JR; Zhou LJ
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2005 Sep; 17(9):544-7. PubMed ID: 16146600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma N-terminal pro-B-type natriuretic peptide concentration helps to predict survival in dogs with symptomatic degenerative mitral valve disease regardless of and in combination with the initial clinical status at admission.
    Serres F; Pouchelon JL; Poujol L; Lefebvre HP; Trumel C; Daste T; Sampedrano CC; Gouni V; Tissier R; Hawa G; Chetboul V
    J Vet Cardiol; 2009 Dec; 11(2):103-21. PubMed ID: 19850546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Influencing factors for the plasma concentration of N-terminal brain natriuretic peptide precursor in patients with heart failure due to various heart diseases].
    Wei BQ; Zhang J; Yang YJ; Zhang YH; Huang XH; Yu LT; Zhou Q; Tan HQ; Yang YM; Wang GG; Zhu J
    Zhonghua Yi Xue Za Zhi; 2011 Oct; 91(38):2683-7. PubMed ID: 22321977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly - a randomised, double-blinded trial.
    Iwanuk N; Nolte I; Wall L; Sehn M; Raue J; Pilgram A; Rumstedt K; Bach JP
    BMC Vet Res; 2019 Jul; 15(1):237. PubMed ID: 31288807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma coenzyme Q
    Svete AN; Verk B; Seliškar A; Tomsič K; Križman PJ; Petrič AD
    Am J Vet Res; 2017 Apr; 78(4):447-457. PubMed ID: 28346005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter evaluation of plasma N-terminal probrain natriuretic peptide (NT-pro BNP) as a biochemical screening test for asymptomatic (occult) cardiomyopathy in cats.
    Fox PR; Rush JE; Reynolds CA; Defrancesco TC; Keene BW; Atkins CE; Gordon SG; Schober KE; Bonagura JD; Stepien RL; Kellihan HB; Macdonald KA; Lehmkuhl LB; Nguyenba TP; Sydney Moise N; Lefbom BK; Hogan DF; Oyama MA
    J Vet Intern Med; 2011; 25(5):1010-6. PubMed ID: 21985136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Markers of oxidative stress in dogs with heart failure.
    Verk B; Nemec Svete A; Salobir J; Rezar V; Domanjko Petrič A
    J Vet Diagn Invest; 2017 Sep; 29(5):636-644. PubMed ID: 28580831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of N-terminal pro-atrial natriuretic peptide and three cardiac biomarkers for discriminatory ability of clinical stage in dogs with myxomatous mitral valve disease.
    Ogawa M; Hori Y; Kanno N; Iwasa N; Toyofuku T; Isayama N; Yoshikawa A; Akabane R; Sakatani A; Miyakawa H; Hsu HH; Miyagawa Y; Takemura N
    J Vet Med Sci; 2021 Apr; 83(4):705-715. PubMed ID: 33551383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis.
    Brueckmann M; Huhle G; Lang S; Haase KK; Bertsch T; Weiss C; Kaden JJ; Putensen C; Borggrefe M; Hoffmann U
    Circulation; 2005 Jul; 112(4):527-34. PubMed ID: 16027260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PATHFAST NT-proBNP (N-terminal-pro B type natriuretic peptide): a multicenter evaluation of a new point-of-care assay.
    Zaninotto M; Mion MM; Di Serio F; Caputo M; Ottomano C; Plebani M
    Clin Chem Lab Med; 2010 Jul; 48(7):1029-34. PubMed ID: 20406130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparison study on diagnostic and prognostic value of N-terminal probrain natriuretic peptide and atrium natriuretic peptide in chronic congestive heart failure].
    Dong H; Chen DQ; Wang Y; Li M
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1740-2. PubMed ID: 18819908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.